imatinib /imă′tĭnib″/ , an inhibitor acting specifically on an abnormal enzyme form that is created by the Philadelphia chromosome abnormality and present in chronic myeloid leukemia. It is administered orally as the mesylate salt in the treatment of chronic myeloid leukemia during blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy.
